High-Dose Convalescent Plasma for Treatment of Severe COVID-19
Gil C De Santis, Luciana Correa Oliveira, Pedro M M Garibaldi, Carlos E L Almado, Julio Croda, Ghislaine G A Arcanjo, Érika A F Oliveira, Adriana C Tonacio, Dante M Langhi Jr, José O Bordin, Renato N Gilio, Leonardo C Palma, Elaine V Santos, Simone K Haddad, Benedito P A Prado Jr, Marjorie Cornejo Pontelli, Rogério Gomes, Carlos H Miranda, Maria Auxiliadora Martins, Dimas T Covas, Eurico Arruda, Benedito A L Fonseca, Rodrigo T Calado
Emerging Infectious Diseases, doi:10.3201/eid2803.212299
C linical signs and symptoms of coronavirus disease (COVID-19) are pleomorphic, varying from none (asymptomatic) to life-threatening. Typical signs/ symptoms are fever, dry cough, dyspnea, fatigue, myalgia, anosmia, and ageusia (1). Radiography or computed tomography of the chest usually reveals bilateral pulmonary ground-glass opacifi cations, mainly in posterior and peripheral areas of the lungs (2). The most common laboratory test alterations are lymphopenia and elevated serum concentrations of infl ammatory biomarkers and D-dimers (3). Risk factors for unfavorable outcomes are older age, concurrent conditions, and perhaps but of lesser importance, blood type A (4,5). Thus far, there is no consensual agreement about specifi c therapy for this disease, despite several attempts to develop one (3,6). More recently, antiviral agents such as MK-4482/EIDD-2801 and PF-07321332 seem to be promising (7,8). In the past, passive antibody transfer by plasma or serum transfusion has been used clinically to treat other infectious diseases, including Ebola, infl uenza A, severe acute respiratory syndrome, and Middle East respiratory syndrome, as well as . The presence of antiviral antibodies, in patient serum or in COVID-19 convalescent plasma (CCP), has been associated with more favorable clinical outcomes (14). Thus, CCP seems to be an attractive therapy because it is a potential source of neutralizing antibodies (15, 16) . The fi rst case series reported from China suggested favorable outcomes for 5 patients receiving undergoing mechanical ventilation who received CCP on days 10-22 after hospital admission (17). Also in China, 10 critically ill patients received 200 mL of CCP with a neutralizing antibody titer of >640, which resulted in undetectable viral load and clinical improvement for 7 of the 10 patients (18). In a nonrandomized
About the Author Dr. De Santis is a clinical hematologist at the University of São Paulo. His research interests include blood transfusion and cellular therapy, such as laboratory support for hematopoietic stem cell transplantation.
References
Abani, Abbas, Abbas, Abbas, Abbasi et al., Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-6736(21)00897-7Address For ; Gil, Santis, Rua Tenente Catão Roxo
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ,
doi:10.1136/bmj.m3939Arabi, Hajeer, Luke, Raviprakash, Balkhy et al., Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia, Emerg Infect Dis,
doi:10.3201/eid2209.151164Avendaño-Solá, Ramos-Martínez, Muñez-Rubio, Ruiz-Antorán, De Molina et al., 19 Study Group. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia, J Clin Invest,
doi:10.1172/JCI152740Bloch, Shoham, Casadevall, Sachais, Shaz et al., Deployment of convalescent plasma for the prevention and treatment of COVID-19, J Clin Invest,
doi:10.1172/JCI138745Bégin, Callum, Jamula, Cook, Heddle et al., CONCOR-1 Study Group. Convalescent plasma for hospitalized patients with COVID-19: an openlabel, randomized controlled trial, Nat Med,
doi:10.1038/s41591-021-01488-2Casadevall, Scharff, Serum therapy revisited: animal models of infection and development of passive antibody therapy, Antimicrob Agents Chemother,
doi:10.1128/AAC.38.8.1695Cox, Wolf, Plemper, Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets, Nat Microbiol,
doi:10.1038/s41564-020-00835-2Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2004168117Garibaldi, Oliveira, Fonseca, Auxiliadora-Martins, Miranda et al., Histo-blood group A is a risk factor for severe COVID-19, Transfus Med,
doi:10.1111/tme.12796Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with Covid-19
Hung, To, Lee, Lee, Yan, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clin Infect Dis,
doi:10.1093/cid/ciq106Joyner, Carter, Senefeld, Klassen, Mills et al., Convalescent plasma antibody levels and the risk of death from COVID-19, N Engl J Med,
doi:10.1056/NEJMoa2031893Körper, Weiss, Zickler, Wiesmann, Zacharowski et al., Trial Group. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19, J Clin Invest,
doi:10.1172/JCI152264Lee, Adhikari, Kwon, Teo, Siemieniuk et al., Anti-Ebola therapy for patients with Ebola virus disease: a systematic review, BMC Infect Dis,
doi:10.1186/s12879-019-3980-9Li, Zhang, Hu, Tong, Zheng et al., Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2020.10044Libster, Marc, Wappner, Coviello, Bianchi et al., Fundación INFANT-COVID-19 Group. Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med,
doi:10.1056/NEJMoa2033700O'donnell, Grinsztejn, Cummings, Justman, Lamb et al., A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19, J Clin Invest,
doi:10.1172/JCI150646Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19, Science,
doi:10.1126/science.abl4784Rosenthal, Cao, Gundrum, Sianis, Safo, Risk factors associated with in-hospital mortality in a us national sample of patients with COVID-19, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2020.29058Sekine, Arns, Fabro, Cipolatt, Machado et al., Study Group. Convalescent plasma for COVID-19 in hospitalised patients: an openlabel, randomised clinical trial, Eur Respir J,
doi:10.1183/13993003.01471-2021Shen, Wang, Zhao, Yang, Li et al., Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA,
doi:10.1001/jama.2020.4783Simonovich, Pratx, Scibona, Beruto, Vallone et al., Study Group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med,
doi:10.1056/NEJMoa2031304Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier et al., SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup, Curr Protoc Microbiol,
doi:10.1002/cpmc.100Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet,
doi:10.1016/S0140-6736(20)31022-9Wendel, Kutner, Machado, Fontão-Wendel, Bub et al., Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program, Transfusion,
doi:10.1111/trf.16065Yokoyama, Wendel, Bonet-Bub, Fachini, Dametto et al., COVID-19 convalescent plasma cohort study: evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes, Transfusion,
doi:10.1111/trf.16573Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3{ 'indexed': {'date-parts': [[2023, 1, 9]], 'date-time': '2023-01-09T09:32:21Z', 'timestamp': 1673256741890},
'reference-count': 33,
'publisher': 'Centers for Disease Control and Prevention (CDC)',
'issue': '3',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2022, 3]]},
'DOI': '10.3201/eid2803.212299',
'type': 'journal-article',
'created': {'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T20:17:38Z', 'timestamp': 1643660258000},
'page': '548-555',
'source': 'Crossref',
'is-referenced-by-count': 10,
'title': 'High-Dose Convalescent Plasma for Treatment of Severe COVID-19',
'prefix': '10.3201',
'volume': '28',
'author': [ {'given': 'Gil C.', 'family': 'De Santis', 'sequence': 'first', 'affiliation': []},
{'given': 'Luciana Correa', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': []},
{'given': 'Pedro M.M.', 'family': 'Garibaldi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Carlos E.L.', 'family': 'Almado', 'sequence': 'additional', 'affiliation': []},
{'given': 'Julio', 'family': 'Croda', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ghislaine G.A.', 'family': 'Arcanjo', 'sequence': 'additional', 'affiliation': []},
{'given': 'Érika A.F.', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': []},
{'given': 'Adriana C.', 'family': 'Tonacio', 'sequence': 'additional', 'affiliation': []},
{ 'suffix': 'Jr.',
'given': 'Dante M.',
'family': 'Langhi',
'sequence': 'additional',
'affiliation': []},
{'given': 'José O.', 'family': 'Bordin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Renato N.', 'family': 'Gilio', 'sequence': 'additional', 'affiliation': []},
{'given': 'Leonardo C.', 'family': 'Palma', 'sequence': 'additional', 'affiliation': []},
{'given': 'Elaine V.', 'family': 'Santos', 'sequence': 'additional', 'affiliation': []},
{'given': 'Simone K.', 'family': 'Haddad', 'sequence': 'additional', 'affiliation': []},
{ 'suffix': 'Jr.',
'given': 'Benedito P.A.',
'family': 'Prado',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Marjorie Cornejo',
'family': 'Pontelli',
'sequence': 'additional',
'affiliation': []},
{'given': 'Rogério', 'family': 'Gomes', 'sequence': 'additional', 'affiliation': []},
{'given': 'Carlos H.', 'family': 'Miranda', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Maria Auxiliadora',
'family': 'Martins',
'sequence': 'additional',
'affiliation': []},
{'given': 'Dimas T.', 'family': 'Covas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Eurico', 'family': 'Arruda', 'sequence': 'additional', 'affiliation': []},
{'given': 'Benedito A.L.', 'family': 'Fonseca', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rodrigo T.', 'family': 'Calado', 'sequence': 'additional', 'affiliation': []}],
'member': '1822',
'reference': [ { 'key': 'key-10.3201/eid2803.212299-202202172242-R1',
'doi-asserted-by': 'publisher',
'first-page': '108634',
'DOI': '10.1016/j.clim.2020.108634',
'article-title': 'COVID-19: A review of therapeutic strategies and vaccine candidates.',
'volume': '222',
'author': 'Izda',
'year': '2021',
'journal-title': 'Clin Immunol'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R2',
'doi-asserted-by': 'publisher',
'first-page': '202',
'DOI': '10.1148/radiol.2020200230',
'article-title': 'CT imaging features of 2019 novel coronavirus (2019-nCoV).',
'volume': '295',
'author': 'Chung',
'year': '2020',
'journal-title': 'Radiology'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R3',
'doi-asserted-by': 'publisher',
'first-page': '1569',
'DOI': '10.1016/S0140-6736(20)31022-9',
'article-title': 'Remdesivir in adults with severe COVID-19: a randomised, double-blind, '
'placebo-controlled, multicentre trial.',
'volume': '395',
'author': 'Wang',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R4',
'doi-asserted-by': 'publisher',
'first-page': 'tme.12796',
'DOI': '10.1111/tme.12796',
'article-title': 'Histo-blood group A is a risk factor for severe COVID-19.',
'author': 'Garibaldi',
'year': '2021',
'journal-title': 'Transfus Med'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R5',
'doi-asserted-by': 'publisher',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'article-title': 'Clinical course and risk factors for mortality of adult inpatients with '
'COVID-19 in Wuhan, China: a retrospective cohort study.',
'volume': '395',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R6',
'doi-asserted-by': 'publisher',
'first-page': '693',
'DOI': '10.1056/NEJMoa2021436',
'article-title': 'Dexamethasone in hospitalized patients with Covid-19.',
'volume': '384',
'author': 'Horby',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R7',
'doi-asserted-by': 'publisher',
'first-page': '11',
'DOI': '10.1038/s41564-020-00835-2',
'article-title': 'Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 '
'blocks SARS-CoV-2 transmission in ferrets.',
'volume': '6',
'author': 'Cox',
'year': '2021',
'journal-title': 'Nat Microbiol'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R8',
'doi-asserted-by': 'publisher',
'first-page': '1586',
'DOI': '10.1126/science.abl4784',
'article-title': 'An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment '
'of COVID-19.',
'volume': '374',
'author': 'Owen',
'year': '2021',
'journal-title': 'Science'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R9',
'doi-asserted-by': 'publisher',
'first-page': '376',
'DOI': '10.1186/s12879-019-3980-9',
'article-title': 'Anti-Ebola therapy for patients with Ebola virus disease: a systematic '
'review.',
'volume': '19',
'author': 'Lee',
'year': '2019',
'journal-title': 'BMC Infect Dis'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R10',
'doi-asserted-by': 'publisher',
'first-page': '1695',
'DOI': '10.1128/AAC.38.8.1695',
'article-title': 'Serum therapy revisited: animal models of infection and development of '
'passive antibody therapy.',
'volume': '38',
'author': 'Casadevall',
'year': '1994',
'journal-title': 'Antimicrob Agents Chemother'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R11',
'doi-asserted-by': 'publisher',
'first-page': '447',
'DOI': '10.1093/cid/ciq106',
'article-title': 'Convalescent plasma treatment reduced mortality in patients with severe '
'pandemic influenza A (H1N1) 2009 virus infection.',
'volume': '52',
'author': 'Hung',
'year': '2011',
'journal-title': 'Clin Infect Dis'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R12',
'doi-asserted-by': 'publisher',
'first-page': '1554',
'DOI': '10.3201/eid2209.151164',
'article-title': 'Feasibility of using convalescent plasma immunotherapy for MERS-CoV '
'infection, Saudi Arabia.',
'volume': '22',
'author': 'Arabi',
'year': '2016',
'journal-title': 'Emerg Infect Dis'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R13',
'doi-asserted-by': 'publisher',
'first-page': '1561',
'DOI': '10.1001/jama.2020.4940',
'article-title': 'Convalescent plasma to treat COVID-19: possibilities and challenges.',
'volume': '323',
'author': 'Roback',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R14',
'doi-asserted-by': 'publisher',
'first-page': '2295',
'DOI': '10.1111/trf.16573',
'article-title': 'COVID-19 convalescent plasma cohort study: Evaluation of the '
'association between both donor and recipient neutralizing antibody '
'titers and patient outcomes.',
'volume': '61',
'author': 'Yokoyama',
'year': '2021',
'journal-title': 'Transfusion'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R15',
'doi-asserted-by': 'publisher',
'first-page': '2757',
'DOI': '10.1172/JCI138745',
'article-title': 'Deployment of convalescent plasma for the prevention and treatment of '
'COVID-19.',
'volume': '130',
'author': 'Bloch',
'year': '2020',
'journal-title': 'J Clin Invest'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R16',
'doi-asserted-by': 'publisher',
'first-page': 'e100',
'DOI': '10.1002/cpmc.100',
'article-title': 'SARS-CoV-2 seroconversion in humans: a detailed protocol for a '
'serological assay, antigen production, and test setup.',
'volume': '57',
'author': 'Stadlbauer',
'year': '2020',
'journal-title': 'Curr Protoc Microbiol'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R17',
'doi-asserted-by': 'publisher',
'first-page': '1582',
'DOI': '10.1001/jama.2020.4783',
'article-title': 'Treatment of 5 critically ill patients with COVID-19 with convalescent '
'plasma.',
'volume': '323',
'author': 'Shen',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R18',
'doi-asserted-by': 'publisher',
'first-page': '9490',
'DOI': '10.1073/pnas.2004168117',
'article-title': 'Effectiveness of convalescent plasma therapy in severe COVID-19 '
'patients.',
'volume': '117',
'author': 'Duan',
'year': '2020',
'journal-title': 'Proc Natl Acad Sci U S A'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R19',
'doi-asserted-by': 'publisher',
'first-page': '1015',
'DOI': '10.1056/NEJMoa2031893',
'article-title': 'Convalescent plasma antibody levels and the risk of death from '
'COVID-19.',
'volume': '384',
'author': 'Joyner',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R20',
'doi-asserted-by': 'publisher',
'first-page': '460',
'DOI': '10.1001/jama.2020.10044',
'article-title': 'Effect of convalescent plasma therapy on time to clinical improvement '
'in patients with severe and life-threatening COVID-19: a randomized '
'clinical trial.',
'volume': '324',
'author': 'Li',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R21',
'doi-asserted-by': 'publisher',
'first-page': '619',
'DOI': '10.1056/NEJMoa2031304',
'article-title': 'PlasmAr Study Group. A randomized trial of convalescent plasma in '
'COVID-19 severe pneumonia.',
'volume': '384',
'author': 'Simonovich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R22',
'unstructured': 'Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, '
'Convalescent plasma or hyperimmune immunoglobulin for people with '
'COVID‐19: a living systematic review [cited 2021 Dec 3]. '
'https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub4/full'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R23',
'doi-asserted-by': 'publisher',
'first-page': '585',
'DOI': '10.1182/asheducation-2018.1.585',
'article-title': 'TACO and TRALI: biology, risk factors, and prevention strategies.',
'volume': '2018',
'author': 'Roubinian',
'year': '2018',
'journal-title': 'Hematology (Am Soc Hematol Educ Program)'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R24',
'doi-asserted-by': 'publisher',
'first-page': '2938',
'DOI': '10.1111/trf.16065',
'article-title': 'Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: '
'Preliminary lessons from a voluntary convalescent donor program.',
'volume': '60',
'author': 'Wendel',
'year': '2020',
'journal-title': 'Transfusion'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R25',
'doi-asserted-by': 'publisher',
'first-page': 'e2029058',
'DOI': '10.1001/jamanetworkopen.2020.29058',
'article-title': 'Risk factors associated with in-hospital mortality in a us national '
'sample of patients with COVID-19.',
'volume': '3',
'author': 'Rosenthal',
'year': '2020',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R26',
'doi-asserted-by': 'publisher',
'first-page': 'e152740',
'DOI': '10.1172/JCI152740',
'article-title': 'A multicenter randomized open-label clinical trial for convalescent '
'plasma in patients hospitalized with COVID-19 pneumonia.',
'volume': '131',
'author': 'Avendaño-Solá',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R27',
'doi-asserted-by': 'publisher',
'first-page': '150646',
'DOI': '10.1172/JCI150646',
'article-title': 'A randomized double-blind controlled trial of convalescent plasma in '
'adults with severe COVID-19.',
'volume': '131',
'author': 'O’Donnell',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R28',
'doi-asserted-by': 'publisher',
'first-page': 'e152264',
'DOI': '10.1172/JCI152264',
'article-title': 'Results of the CAPSID randomized trial for high-dose convalescent '
'plasma in patients with severe COVID-19.',
'volume': '131',
'author': 'Körper',
'year': '2021',
'journal-title': 'J Clin Invest'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R29',
'doi-asserted-by': 'publisher',
'first-page': '2101471',
'DOI': '10.1183/13993003.01471-2021',
'article-title': 'Convalescent plasma for COVID-19 in hospitalised patients: an '
'open-label, randomised clinical trial.',
'author': 'Sekine',
'year': '2021',
'journal-title': 'Eur Respir J'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R30',
'doi-asserted-by': 'publisher',
'first-page': 'm3939',
'DOI': '10.1136/bmj.m3939',
'article-title': 'Convalescent plasma in the management of moderate covid-19 in adults in '
'India: open label phase II multicentre randomised controlled trial '
'(PLACID Trial).',
'volume': '371',
'author': 'Agarwal',
'year': '2020',
'journal-title': 'BMJ'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R31',
'doi-asserted-by': 'publisher',
'first-page': '2049',
'DOI': '10.1016/S0140-6736(21)00897-7',
'article-title': 'Convalescent plasma in patients admitted to hospital with COVID-19 '
'(RECOVERY): a randomised controlled, open-label, platform trial.',
'volume': '397',
'author': 'Abani',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R32',
'doi-asserted-by': 'publisher',
'first-page': '2012',
'DOI': '10.1038/s41591-021-01488-2',
'article-title': 'Convalescent plasma for hospitalized patients with COVID-19: an '
'open-label, randomized controlled trial.',
'volume': '27',
'author': 'Bégin',
'year': '2021',
'journal-title': 'Nat Med'},
{ 'key': 'key-10.3201/eid2803.212299-202202172242-R33',
'doi-asserted-by': 'publisher',
'first-page': '610',
'DOI': '10.1056/NEJMoa2033700',
'article-title': 'Early high-titer plasma therapy to prevent severe COVID-19 in older '
'adults.',
'volume': '384',
'author': 'Libster',
'year': '2021',
'journal-title': 'N Engl J Med'}],
'container-title': 'Emerging Infectious Diseases',
'original-title': [],
'deposited': { 'date-parts': [[2022, 2, 23]],
'date-time': '2022-02-23T17:05:39Z',
'timestamp': 1645635939000},
'score': 1,
'resource': {'primary': {'URL': 'https://wwwnc.cdc.gov/eid/article/28/3/21-2299_article.htm'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3]]},
'references-count': 33,
'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2022, 3]]}},
'URL': 'http://dx.doi.org/10.3201/eid2803.212299',
'relation': {},
'ISSN': ['1080-6040', '1080-6059'],
'subject': ['Infectious Diseases', 'Microbiology (medical)', 'Epidemiology'],
'container-title-short': 'Emerg. Infect. Dis.',
'published': {'date-parts': [[2022, 3]]}}
